Results 141 to 150 of about 4,911,045 (202)

M5 positive allosteric modulation alleviates parkinsonian motor deficits. [PDF]

PLoS One
Chambers NE, Hall D, Kaplan M, Garan S, Eichner T, Moehle MS.   +5 more
europepmc   +1 more source

Long-Duration Response to Levodopa in Patients with Early Parkinson's Disease: Pharmacodynamics, Neuroplasticity, and Clinical Implications. [PDF]

Biomedicines
Sciacca G.
europepmc   +1 more source

Distinct contributions of two subpopulations of subthalamic neurons to levodopa-induced dyskinesia. [PDF]

Sci Adv
Shen B, Han L, Xiao Y, Shen C, Le Z, Wu B, Su L, Yu W, Sun Y, Liu F, Yao H, Wu J, Wang J.   +12 more
europepmc   +1 more source

A dual timeline of safinamide effects in Parkinson's disease: mechanistic rationale and clinical implications. [PDF]

Front Neurol
Bhidayasiri R, Suansanae T.
europepmc   +1 more source

Preclinical human models of primary ciliary dyskinesia. [PDF]

Eur Respir Rev
Ong JWY, Jackson CL, Arbi M, Hart SL, Mill P, Paff T, Rubbo B, Shahaj E, Shoemark A, Lucas JS.   +9 more
europepmc   +1 more source

Drug-induced dyskinesia--an electrophysiological analysis of dyskinesia induced by L-DOPA and anticholinergic drugs.

Nagoya journal of medical science, 1973
openaire   +2 more sources

Electroconvulsive Therapy for Severe Refractory Tardive Dystonia Without Active Depression: A Case Report. [PDF]

Neuropsychopharmacol Rep
Asahi T, Kawamata Y, Sugawara N, Maehara R, Yasui-Furukori N.   +4 more
europepmc   +1 more source

Data-Driven Insights into Hyperkinetic Disorders in Neurodevelopmental Syndromes and Epileptic Encephalopathies. [PDF]

Mov Disord Clin Pract
Morales-Briceño H, Mohammad SS, Angiti RR, Han V, Tchan M, Dale RC, Fung VSC.   +6 more
europepmc   +1 more source